[go: up one dir, main page]

ES2190486T3 - 3-acetidinilalquilpiperidinas o -pirrolidinas como antagonistas de la taquicinina. - Google Patents

3-acetidinilalquilpiperidinas o -pirrolidinas como antagonistas de la taquicinina.

Info

Publication number
ES2190486T3
ES2190486T3 ES96943119T ES96943119T ES2190486T3 ES 2190486 T3 ES2190486 T3 ES 2190486T3 ES 96943119 T ES96943119 T ES 96943119T ES 96943119 T ES96943119 T ES 96943119T ES 2190486 T3 ES2190486 T3 ES 2190486T3
Authority
ES
Spain
Prior art keywords
antagonists
tagicinine
pirrolidins
alkylpiperidins
acetidinyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96943119T
Other languages
English (en)
Inventor
Alexander Roderick Mackenzie
Allan Patrick Marchington
Donald Stuart Middleton
Sandra Dora Meadows
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Research and Development Co NV SA
Original Assignee
Pfizer Research and Development Co NV SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Research and Development Co NV SA filed Critical Pfizer Research and Development Co NV SA
Application granted granted Critical
Publication of ES2190486T3 publication Critical patent/ES2190486T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/12Mucolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C07D211/32Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrane Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

LA PRESENTE INVENCION PROPONE COMPUESTOS DE FORMULA (I) Y SUS SALES FARMACEUTICAMENTE ACEPTABLES. TALES COMPUESTOS Y SALES SON ANTAGONISTAS DE LA TAQUICININA.
ES96943119T 1996-01-05 1996-12-09 3-acetidinilalquilpiperidinas o -pirrolidinas como antagonistas de la taquicinina. Expired - Lifetime ES2190486T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9600235.7A GB9600235D0 (en) 1996-01-05 1996-01-05 Therapeutic agents

Publications (1)

Publication Number Publication Date
ES2190486T3 true ES2190486T3 (es) 2003-08-01

Family

ID=10786682

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96943119T Expired - Lifetime ES2190486T3 (es) 1996-01-05 1996-12-09 3-acetidinilalquilpiperidinas o -pirrolidinas como antagonistas de la taquicinina.

Country Status (38)

Country Link
US (1) US6242438B1 (es)
EP (1) EP0871623B1 (es)
JP (2) JP3123611B2 (es)
KR (1) KR100275402B1 (es)
AP (1) AP709A (es)
AR (2) AR005339A1 (es)
AT (1) ATE232526T1 (es)
AU (1) AU708282B2 (es)
BG (1) BG102589A (es)
BR (1) BR9612412A (es)
CA (1) CA2237189C (es)
CO (1) CO4750815A1 (es)
CZ (1) CZ209398A3 (es)
DE (1) DE69626220T2 (es)
DK (1) DK0871623T3 (es)
DZ (1) DZ2155A1 (es)
ES (1) ES2190486T3 (es)
GB (1) GB9600235D0 (es)
HR (1) HRP970006A2 (es)
HU (1) HUP9903590A3 (es)
IL (2) IL124309A (es)
IS (1) IS1876B (es)
MA (1) MA26417A1 (es)
NO (1) NO311838B1 (es)
NZ (1) NZ324712A (es)
OA (1) OA10863A (es)
PE (1) PE29798A1 (es)
PL (1) PL185723B1 (es)
RU (1) RU2158264C2 (es)
SI (1) SI0871623T1 (es)
SK (1) SK89598A3 (es)
TN (1) TNSN96174A1 (es)
TR (1) TR199801268T2 (es)
TW (1) TW472054B (es)
UY (1) UY24429A1 (es)
WO (1) WO1997025322A1 (es)
YU (1) YU71496A (es)
ZA (1) ZA9747B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9714129D0 (en) * 1997-07-04 1997-09-10 Pfizer Ltd Azetidines
WO1999019297A1 (en) * 1997-10-15 1999-04-22 Coelacanth Chemical Corporation Synthesis of azetidine derivatives
EP1048658B1 (en) 1997-12-04 2005-06-15 Sankyo Company Limited Alicyclic acylated heterocyclic derivatives
GB9821898D0 (en) * 1998-10-08 1998-12-02 Pfizer Ltd Heterocycles
NZ523310A (en) * 2000-06-12 2005-07-29 Univ Rochester Tachykinin receptor antagonist to block receptors NK1, NK2, and NK3 and treat symptoms of hormonal variation
US6642226B2 (en) * 2001-02-06 2003-11-04 Hoffman-La Roche Inc. Substituted phenyl-piperidine methanone compounds
GB0130261D0 (en) * 2001-12-18 2002-02-06 Pfizer Ltd Lactams as tachykinin antagonists
RU2337909C2 (ru) * 2002-02-01 2008-11-10 Ф.Хоффманн-Ля Рош Аг Замещенные индолы и фармацевтическая композиция, обладающая агонистической активностью в отношении альфа-1a/l адренорецептора
US7674783B2 (en) * 2002-11-22 2010-03-09 Dimera Inc. Estrogen beta receptor agonists to prevent or reduce the severity of cardiovascular disease
AU2003299249B2 (en) * 2002-12-23 2010-05-27 Janssen Pharmaceutica N.V. Substituted 1-piperidin-4-yl-4-azetidin-3-yl-piperazine derivatives and their use as neurokinin antagonists
TW200508221A (en) 2003-06-13 2005-03-01 Astrazeneca Ab New azetidine compounds
EP1498123A1 (en) * 2003-07-18 2005-01-19 Aventis Pharma S.A. Emulsifying systems containing azetidine derivatives
JP2008504275A (ja) 2004-06-24 2008-02-14 インサイト・コーポレイション N−置換ピペリジンおよびその医薬としての使用
CA2589565A1 (en) * 2004-06-24 2006-01-05 Incyte Corporation Amido compounds and their use as pharmaceuticals
ES2350647T3 (es) 2005-03-08 2011-01-25 Janssen Pharmaceutica Nv Derivados de diaza-espiro-[4.4]-nonano como antagonistas de neuroquininas (nk1).
AR057828A1 (es) 2005-09-29 2007-12-19 Astrazeneca Ab Compuestos derivados de azetidina, su preparacion y composicion farmaceuutica
US8106208B2 (en) 2006-05-18 2012-01-31 Albireo Ab Benzamide compounds that act as NK receptor antagonists
KR20090112722A (ko) 2007-01-24 2009-10-28 글락소 그룹 리미티드 3,5-디아미노-6-(2,3-디클로로페닐)-1,2,4-트리아진 또는 r(-)-2,4-디아미노-5-(2,3-디클로로페닐)-6-플루오로메틸 피리미딘 및 nk1을 포함하는 제약 조성물
RU2402546C2 (ru) * 2008-11-20 2010-10-27 Федеральное государственное учреждение "27 Научный центр Министерства Обороны Российской Федерации" Способ получения метил 4-[(3,4-дихлорфенил)ацетил]-3-[(1-пирролидинил)метил]-1-пиперазинкарбоксилата
TW201026666A (en) * 2008-12-16 2010-07-16 Astrazeneca Ab Quaternary piperidine derivatives and uses thereof
KR20120035146A (ko) * 2009-04-22 2012-04-13 얀센 파마슈티카 엔.브이. 모노아실글리세롤 리파아제 억제제로서의 아제티디닐 다이아미드

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4226998A (en) * 1974-09-26 1980-10-07 Ciba-Geigy Corporation 1-Benzothiepin-4-carboxamides
GB1600880A (en) * 1978-05-23 1981-10-21 Lilly Industries Ltd Pharmaceutical compositions comprising hydantoin derivatives
SU1032752A1 (ru) * 1981-08-14 1990-11-07 Институт биохимии АН ЛитССР Калиева соль 4-(пиперидиназо)-N-ацетилбензолсульфамида, обладающа противовоспалительной активностью
SE8904298D0 (sv) * 1989-12-21 1989-12-21 Astra Ab New compounds
IL99320A (en) * 1990-09-05 1995-07-31 Sanofi Sa Arylalkylamines, their preparation and pharmaceutical compositions containing them
FR2676055B1 (fr) * 1991-05-03 1993-09-03 Sanofi Elf Composes polycycliques amines et leurs enantiomeres, procede pour leur preparation et compositions pharmaceutiques les contenant.
NZ267209A (en) * 1993-05-06 1997-09-22 Merrell Dow Pharma Substituted pyrrolidin-3-yl-alkyl-piperidine derivatives, preparation and pharmaceutical compositions thereof
GB9315808D0 (en) * 1993-07-30 1993-09-15 Merck Sharp & Dohme Therapeutic agents
CA2180746A1 (en) * 1994-01-13 1995-07-20 Raymond Baker Gem-disubstituted azacyclic tachykinin antagonists
FR2719311B1 (fr) * 1994-03-18 1998-06-26 Sanofi Sa Composés antagonistes sélectifs du récepteur NK3 humain et leur utilisation comme médicaments et outils de diagnostic.
FR2717804B1 (fr) 1994-03-25 1996-06-21 Sanofi Sa Sels de composés hétéroaromatiques azotés substitués, procédé pour leur préparation et compositions pharmaceutiques en contenant.
TW432061B (en) * 1994-08-09 2001-05-01 Pfizer Res & Dev Lactams
IL125002A0 (en) 1995-12-20 1999-01-26 Hoechst Marion Roussel Inc Novel substituted 4-(1H-benzimidazol-2-yl) [1,4] diazepanes useful for the treatment of allergic diseases
GB9601202D0 (en) * 1996-01-22 1996-03-20 Pfizer Ltd Piperidones
GB9812037D0 (en) * 1998-06-04 1998-07-29 Pfizer Ltd Piperidones
GB9821898D0 (en) * 1998-10-08 1998-12-02 Pfizer Ltd Heterocycles

Also Published As

Publication number Publication date
IS4760A (is) 1998-05-28
BR9612412A (pt) 1999-07-13
AP9600901A0 (en) 1997-01-31
YU71496A (en) 1999-11-22
CO4750815A1 (es) 1999-03-31
JP2000344741A (ja) 2000-12-12
HUP9903590A3 (en) 2002-01-28
OA10863A (en) 2001-09-27
GB9600235D0 (en) 1996-03-06
HRP970006A2 (en) 1998-06-30
DE69626220D1 (de) 2003-03-20
PE29798A1 (es) 1998-06-11
PL185723B1 (pl) 2003-07-31
US6242438B1 (en) 2001-06-05
SK89598A3 (en) 2000-02-14
IL124309A (en) 2002-11-10
RU2158264C2 (ru) 2000-10-27
DZ2155A1 (fr) 2002-10-26
JP3123611B2 (ja) 2001-01-15
AU1195097A (en) 1997-08-01
CA2237189A1 (en) 1997-07-17
AR005339A1 (es) 1999-04-28
TW472054B (en) 2002-01-11
NO311838B1 (no) 2002-02-04
BG102589A (en) 1999-09-30
TR199801268T2 (xx) 1998-10-21
NO982651D0 (no) 1998-06-09
PL327665A1 (en) 1998-12-21
TNSN96174A1 (fr) 2005-03-15
CA2237189C (en) 2002-09-03
AP709A (en) 1998-12-22
UY24429A1 (es) 2001-08-27
DE69626220T2 (de) 2003-08-28
NZ324712A (en) 1999-05-28
AR005338A1 (es) 1999-04-28
DK0871623T3 (da) 2003-03-31
ZA9747B (en) 1998-09-30
KR19990077027A (ko) 1999-10-25
ATE232526T1 (de) 2003-02-15
CZ209398A3 (cs) 1999-04-14
IS1876B (is) 2003-05-28
IL124309A0 (en) 1998-12-06
JPH11501667A (ja) 1999-02-09
HUP9903590A2 (hu) 2000-05-28
AU708282B2 (en) 1999-07-29
KR100275402B1 (ko) 2000-12-15
WO1997025322A1 (en) 1997-07-17
EP0871623A1 (en) 1998-10-21
MA26417A1 (fr) 2004-12-20
JP3254205B2 (ja) 2002-02-04
NO982651L (no) 1998-06-09
EP0871623B1 (en) 2003-02-12
IL145324A0 (en) 2002-06-30
SI0871623T1 (en) 2003-08-31

Similar Documents

Publication Publication Date Title
ES2190486T3 (es) 3-acetidinilalquilpiperidinas o -pirrolidinas como antagonistas de la taquicinina.
AR003466A1 (es) Compuestos 14-hidroxi-2-desoxoparahercuamida b
PA8436201A1 (es) Derivados 6,5-heterobiciclicos sustituidos
ES2170252T3 (es) Tetrahidroimidazopiridoindoldionas como inhibidores de cgmp especifico pde.
EA199700061A1 (ru) Способ получения силденафила
ES2145318T3 (es) Imidazo(4,5-c)quinolin-aminas.
AR010062A1 (es) Nuevos benzamidaldehidos y su utilizacion
DK1413582T3 (da) Dimere pyrrolobenzodiazepiner
EA199900373A2 (ru) Фармацевтические композиции
TR199902400T2 (xx) Fungusit etkinlik g�steren terkiplerin birle�imleri.
CY1108610T1 (el) Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες
GR960100438A (el) Νεα παρασιτοκτονα.
ES2184149T3 (es) Paclitaxeles 6-tio sustituidos.
HN1998000086A (es) Derivados de 9 - desofo - 9 aza - 9a - homoeritromicina a - c - 4 sustituidos.
SV1997000079A (es) Dihidrato d de olancepina ref. x- 11062t
TR200201505T2 (tr) Terapötik maddeler olarak pirazolopirimidinler
ES2193508T3 (es) Ftalizinonas.
MX9102407A (es) 4 arilpiperazinas y 4-arilpiperidinas novedosas.
ES2191208T3 (es) Oxiimino-pregnano-carbolactonas.
IT1285770B1 (it) Composti corticoidei
NO993350L (no) Vitronectin-reseptor-antagonister
NO965516D0 (no) Sterolderivater anvendt til regulering av meiose
TR199802240T2 (es)
MX9302116A (es) Compuestos azabiciclo.
ATE203519T1 (de) Chinolinderivate als antimalariamittel